| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $191,555,714 ) (Continued on the next page) |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL173059 | Defining neutrophil pathobiology in pediatric Long COVID | 000 | 1 | NIH | 4/22/2024 | $745,411 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA283214 | Interleukin 33 Regulation for Cancer Prevention in Chronic Inflammation | 000 | 1 | NIH | 3/28/2024 | $604,063 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA276115 | Interplay of natural killer cells and extracellular matrix proteins in solid cancers | 000 | 1 | NIH | 3/27/2024 | $660,987 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI177414 | Staphylococcal protease-mediated epithelial barrier perturbation and allergen sensitization | 001 | 1 | NIH | 2/1/2024 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI177414 | Staphylococcal protease-mediated epithelial barrier perturbation and allergen sensitization | 000 | 1 | NIH | 1/18/2024 | $589,351 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01EB034197 | Plug-and-play Hyperpolarized MRI of Metabolism on Clinical Scanners | 000 | 1 | NIH | 1/17/2024 | $538,475 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL166266 | Heterogeneity of bone marrow cavities shaping the hematopoietic microenvironment | 000 | 1 | NIH | 11/21/2023 | $734,642 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01NS134784 | Development of in Vivo Base Editing as a Genetic Treatment for Spinal Muscular Atrophy | 000 | 1 | NIH | 1/17/2024 | $244,458 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21NS137436 | Wearable NIRS Device for Continuous Monitoring of Cytochrome C Oxidase in Hypoxic Ischemic Encephalopathy | 000 | 1 | NIH | 3/27/2024 | $250,500 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99CA286969 | Breaching the Tumor-Immune Mechanical Barrier for Optimal Antitumor Immunity | 000 | 1 | NIH | 1/17/2024 | $176,040 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21CA279248 | Innovating CBT-I for Cancer Survivors: An Optimization Trial | 000 | 1 | NIH | 4/23/2024 | $187,935 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01NS134784 | Development of in Vivo Base Editing as a Genetic Treatment for Spinal Muscular Atrophy | 001 | 1 | NIH | 2/5/2024 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01CA279316 | Impact of Cancer on Cognitive Trajectories in Older Adults | 000 | 1 | NIH | 4/5/2024 | $526,951 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01DK131543 | Normothermic perfusion of steatotic livers for transplantation | 000 | 1 | NIH | 1/31/2024 | $268,000 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99DK136365 | Impact of HIV-associated intestinal CD8+ T cell function in mucosal homeostasis | 000 | 1 | NIH | 2/1/2024 | $91,500 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K23MH132893 | The role of inflammation in cognitive dysfunction in acute depression as determined by experimental inhibition of tumor necrosis factor-alphasignaling in a randomized controlled trial. | 000 | 1 | NIH | 2/1/2024 | $197,115 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21CA286215 | A multimodal single-cell approach to developing personalized combinatorial treatments for glioblastoma | 000 | 1 | NIH | 1/22/2024 | $249,832 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI175345 | Antibody mediated immunity against Klebsiella pneumoniae | 000 | 1 | NIH | 11/30/2023 | $660,621 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01GM152809 | Automated technology for the preservation of Drosophila embryos | 000 | 1 | NIH | 1/23/2024 | $567,229 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131347 | Comparative effectiveness of EEG-guided anti-seizure treatment in acute brain injury | 000 | 1 | NIH | 11/30/2023 | $698,062 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI174276 | Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery | 000 | 1 | NIH | 1/8/2024 | $350,000 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI174276 | Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery | 000 | 1 | NIH | 1/8/2024 | $472,056 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS127353 | Mapping human neurocircuitry across scales with diffusion MRI and optical imaging | 000 | 5 | NIH | 4/10/2024 | $632,897 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21MH135201 | Multi-modal imaging of the metabolic and neurochemical mechanisms underlying task-evoked negative BOLD signals | 000 | 1 | NIH | 11/27/2023 | $250,500 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | F32HL174327 | Genetics of carotid artery disease progression among patients who have failed non-operative management | 000 | 1 | NIH | 3/20/2024 | $87,792 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K22CA282019 | Boosting IL-12-induced anti-glioblastoma activity via immunotherapeutic extracellular vesicles. | 000 | 1 | NIH | 11/30/2023 | $160,537 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08MH135343 | Understanding developmental neurogenomic mechanisms in externalizing disorders | 000 | 1 | NIH | 11/30/2023 | $196,083 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01MH135131 | Improving emergency psychiatric care through machine learning, causal inference, and psychometrics | 002 | 1 | NIH | 2/7/2024 | $13,790 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01MH135131 | Improving emergency psychiatric care through machine learning, causal inference, and psychometrics | 000 | 1 | NIH | 11/17/2023 | $167,556 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01MH135131 | Improving emergency psychiatric care through machine learning, causal inference, and psychometrics | 001 | 1 | NIH | 12/29/2023 | $0 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08NS131530 | Causes and Consequences of Leptomeningeal Bleeding in Cerebral Amyloid Angiopathy | 000 | 1 | NIH | 11/27/2023 | $230,071 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01AG084820 | Neurogenetic contributions to the spread of tau pathology in sporadic early-onset Alzheimer's disease | 000 | 1 | NIH | 11/28/2023 | $129,075 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01DK135854 | Prediction of outcomes in diverticulitis using a deep-learning framework | 000 | 1 | NIH | 1/12/2024 | $157,744 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS136385 | Resolving Human Brain Activation Across Cerebral Cortical Layers with Line-Scan Functional MRI | 000 | 1 | NIH | 3/12/2024 | $640,199 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS134597 | Development of real-world motor outcome measures in ataxia-telangiectasia | 000 | 1 | NIH | 12/14/2023 | $691,502 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131281 | Targeting receptor interacting protein kinase-1 in the chronic period of intracerebral hemorrhage | 001 | 1 | NIH | 2/21/2024 | -$43,061 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131281 | Targeting receptor interacting protein kinase-1 in the chronic period of intracerebral hemorrhage | 001 | 1 | NIH | 2/21/2024 | $108,562 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01HL169015 | Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial | 000 | 1 | NIH | 3/6/2024 | $773,364 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS131281 | Targeting receptor interacting protein kinase-1 in the chronic period of intracerebral hemorrhage | 000 | 1 | NIH | 12/13/2023 | $464,068 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R34MH134698 | TENDAI4PrEP: Adaptation of a problem-solving intervention to address individual and provider level barriers to PrEP uptake and adherence among pregnant persons in Zimbabwe | 000 | 1 | NIH | 4/20/2024 | $215,900 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AR082401 | Neuronal MRGPR signaling in itch and allergic skin inflammation | 000 | 1 | NIH | 12/6/2023 | $608,982 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AI179741 | Non-Templated Regulation of IgE Mediated Anaphylaxis | 000 | 1 | NIH | 11/16/2023 | $781,172 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01NS136224 | Brain Stimulation to Improve Neurocognitive Deficits After Subarachnoid Hemorrhage | 000 | 1 | NIH | 4/16/2024 | $477,237 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R21AI180866 | Does age matter for the development of pathogenic T helper 2 resident memory cells in the lung? | 000 | 1 | NIH | 11/22/2023 | $225,450 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R61CA287026 | A Real-Time AI-Driven High-Throughput Proteomics Data Acquisition Method for Clinical Applications | 000 | 1 | NIH | 2/12/2024 | $234,218 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K08HL168238 | Advancing the clinical actionability of polygenic scores for coronary artery disease | 000 | 1 | NIH | 12/11/2023 | $170,323 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K01HL168231 | Deep learning to assess cardiovascular disease risk from chest imaging | 000 | 1 | NIH | 12/11/2023 | $175,147 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | R01AG085562 | Development of sensitive PET tracers of pan-Amyloid-beta species for Alzheimer's disease | 000 | 1 | NIH | 12/4/2023 | $826,732 |
| 2024 | 2024 | THE GENERAL HOSPITAL CORPORATION | 55 FRUIT ST | BOSTON | MA | 02114-2621 | SUFFOLK | USA | K99NS132984 | Revealing the Functional and Microstructural Response of Human Hippocampus to Spatial Learning with High-Gradient Strength Diffusion MRI | 000 | 1 | NIH | 2/8/2024 | $163,327 |
|